Analysing demand and cost of toric IOLs in hospitals


Study results help shed light on using toric IOLs on corneal astigmatism patients

"We were interested in understanding our patient demographic in greater detail so as to establish the need for toric lens provision. We could then plan its probable cost and implementation," said Dr Muhtaseb, previous consultant ophthalmologist at the Singleton Hospital Abertawe Bro Morgannwg University NHS Trust, Swansea, UK.

Compiling the study

At the time of cataract surgery a toric IOL (Rayner TFlex, UK) was implanted to correct for the corneal astigmatism. "We did not consider analysing wavefront errors or other data," added Dr Muhtaseb, "Our focus was on the main element of a patient's clinical picture that we could treat and that would greatly affect the quality of the surgical outcome."

There were minimal factors affecting the results. Dr Mohammed explained. "All patients were seen in the same department by one of the same four technicians, all using the same model of IOL Master, and all patients had surgery using the same model of phacoemulsification device (Storz Millennium)."

Beneficial to hospitals

The measured corneal astigmatism of the majority of the study group (79.5%) was 1.5 D or less. A little less than a quarter of the patients involved in the study had a corneal astigmatism of 0.5 D or less and only about 6.5% of the patients had a corneal astigmatism of more than 1.5 D. This data will prove useful to hospitals in determining the level of need for toric IOLs and how much it will cost to implement the use of these lenses in this setting.

"The data from this study shouldn't only be confined to NHS practices," according to Dr Muhtaseb. "These findings will also benefit patients being treated in private practice." He noted that further clinical data from a greater patient population and using a dedicated corneal topographer could offer a more clinically 'ideal' situation to this type of study, however, the IOLMaster was used as it is practical and relevant to a real-life scenario for many surgeons. In the future, Dr Muhtaseb would like to proceed with a further study of the clinical outcomes and patient satisfaction after toric IOL implantation.

"We hope, however, that our study has added weight to the currently available literature that supports the use of toric IOLs through demonstrating the need for them," concluded Dr Muhtaseb.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.